Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPATE vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, enhancing serotonergic neurotransmission.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Major depressive disorder,Generalized anxiety disorder,Panic disorder,Social anxiety disorder,Obsessive-compulsive disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Hypertension
50 mg orally once daily.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal half-life of 12-15 hours (range 10-18h) in adults; prolonged in renal impairment (up to 30h in severe cases).
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Hepatic primarily via CYP2C19, CYP2D6, CYP3A4, and CYP2C9; active metabolite desmethylsertraline.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily renal excretion of unchanged drug (60-80%); biliary/fecal elimination accounts for 15-20%.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
95-98% bound, primarily to albumin and alpha-1-acid glycoprotein.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
0.5-0.7 L/kg (suggests moderate tissue penetration; primarily extracellular distribution).
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral: 70-80% (first-pass metabolism 20-30%; food reduces absorption by 10-15%).
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
No dosage adjustment required for GFR ≥30 m L/min; GFR <30 m L/min: not recommended.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: 25 mg once daily; Child-Pugh C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not approved for pediatric use.
Not established; avoid use in children.
No dosage adjustment required; monitor renal function.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
None
Suicidality risk in pediatric/young adult patients,Serotonin syndrome risk with concomitant serotonergic drugs,Bleeding risk with anticoagulants/antiplatelets,Activation of mania/hypomania,Seizure risk in patients with epilepsy,Angle-closure glaucoma risk,Hyponatremia risk in elderly/dehydrated patients,Discontinuation syndrome with abrupt cessation
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Concurrent MAOIs (including linezolid and methylene blue),Concurrent pimozide,Known hypersensitivity to sertraline
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Grapefruit and grapefruit juice may increase sertraline levels; avoid consumption.,Alcohol: Avoid or limit intake to prevent worsening of side effects and reduced drug efficacy.,St. John's Wort: Concomitant use increases risk of serotonin syndrome; avoid.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
SERPATE is contraindicated in pregnancy. First trimester exposure carries risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. For all trimesters, increased risk of spontaneous abortion and stillbirth has been reported.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
SERPATE is excreted into human breast milk. Milk-to-plasma ratio is approximately 2:1. Breastfeeding is not recommended during therapy due to potential for severe adverse reactions in the nursing infant. Advise women to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Due to significant pharmacokinetic changes in pregnancy, including increased clearance (by 50%) and expanded volume of distribution, the dose of SERPATE should be increased by 30% during the second and third trimesters. Monitor therapeutic drug levels to maintain trough concentrations within the target range. Postpartum, reduce to prepregnancy dose within 48 hours to avoid toxicity.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
SERPATE is a brand name for sertraline, a selective serotonin reuptake inhibitor (SSRI). Initiate at 25-50 mg daily, titrate up to 200 mg maximum. Monitor for serotonin syndrome, especially with other serotonergic drugs. Abrupt discontinuation may cause withdrawal symptoms; taper gradually. Use with caution in bipolar disorder due to risk of manic switching. Adjusted dosing may be needed in hepatic impairment; no adjustment for renal impairment. May increase risk of bleeding, especially with NSAIDs or anticoagulants. Monitor for hyponatremia in elderly or volume-depleted patients.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take sertraline exactly as prescribed, usually once daily with or without food.,It may take 2-4 weeks to feel full benefit; do not stop abruptly without consulting your doctor.,Common side effects include nausea, diarrhea, dry mouth, dizziness, and trouble sleeping; these often improve over time.,Contact your doctor immediately if you experience signs of serotonin syndrome (e.g., agitation, hallucinations, fever, fast heart rate, muscle stiffness, twitching, coordination problems) or bleeding (e.g., unusual bruising, nosebleeds).,Avoid alcohol, as it can worsen side effects and reduce drug effectiveness.,Inform all healthcare providers that you are taking sertraline, especially before surgery or any procedure.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks and benefits with your doctor.,Do not take with MAO inhibitors (e.g., linezolid, methylene blue) or within 14 days of stopping them.,Store at room temperature away from moisture and heat.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPATE vs ALDORIL 25, answered by our medical review team.
SERPATE is a Antihypertensive that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, enhancing serotonergic neurotransmission.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPATE and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPATE is: 50 mg orally once daily.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPATE and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPATE is classified as Category C. SERPATE is contraindicated in pregnancy. First trimester exposure carries risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second . ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.